eligibility_summary
Adults 18–75 with eligible R/R LBCL after first‑line anthracycline+anti‑CD20 with early relapse or 2nd‑line failure. Need PET+, tissue, ECOG 0–1, adequate organ function/life expectancy, contraception. Exclusions: CNS disease, ≥3 prior lines, autoimmune needing immunosuppression, prior allo/solid transplant, other cancer <2y, prohibited prior/recent therapy (e.g., CAR‑T/CD19), active infection (HBV/HCV) or live vaccine, cardiac disease, inability to consent/registry refusal.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial of WZTL-002, an autologous third-generation anti-CD19 CAR T-cell (biologic) for relapsed/refractory large B-cell lymphoma. WZTL-002 expresses a CD19-specific scFv with intracellular CD28 and CD3z activation domains plus a Toll-like receptor 2 (TLR2) co-stimulatory module (1928T2z) to enhance T-cell activation, cytokine production, and persistence. Lymphodepletion before infusion uses fludarabine (drug, purine-analog antimetabolite) and cyclophosphamide (drug, alkylating agent) to deplete host lymphocytes and support CAR T expansion. Targets: CD19+ malignant B cells (and normal B cells, causing B-cell aplasia), key pathways are CD19 engagement with downstream CD28/CD3z T-cell receptor signaling and TLR2 co-stimulation, lymphodepletion targets proliferating lymphocytes.